Japan ANCA Vasculitis Treatment Market

Japan ANCA Vasculitis Treatment Market Summary:

According to Transpire Insights, a detailed research report on the market reflects that the Japan ANCA Vasculitis Treatment Market was valued at approximately USD 43.8 million in 2025 and is expected to reach USD 46.2 million in 2026, further expanding to an estimated USD 69.8 million by 2033, registering a CAGR of 6.07% during the forecast period 2026–2033. The market is witnessing steady development, supported by advancements in ANCA vasculitis diagnosis and treatment, expanding therapeutic capabilities, improved patient management approaches, and ongoing innovation in treatment modalities, which collectively contribute to Japan market development, clinical innovation, expanding healthcare capabilities, and overall market growth dynamics.

Market Snapshot

• Market Value (2025): USD 43.8 Million.
• Expected Market Value (2026): USD 46.2 Million.
• Estimated Market Value (2033): USD 69.8 Million.
• Forecast CAGR (2026–2033): 6.07%.

Introduction

The Japan ANCA-Associated Vasculitis (AAV) Treatment Market includes pharmaceutical drugs, biologic agents, and clinical therapies used to manage and achieve remission in ANCA-associated vasculitis, a rare autoimmune disorder characterized by inflammation of small blood vessels and significant damage to the kidneys and lungs. This market includes core disease subtypes, Microscopic Polyangiitis (MPA), Granulomatosis with Polyangiitis (GPA) and Eosinophilic Granulomatosis with Polyangiitis (EGPA) that require different diagnostic and treatment approaches. Treatments include traditional corticosteroids and immunosuppressants as well as newer biologic and targeted oral medications. This market is a niche segment of the broader rare disease immunology market in Japan and is subject to the changing trends in treatment practices, regulatory approvals, and the increasing demand from the clinical setting. It is a significant area of focus within the autoimmune and nephrology-pulmonology treatment landscape in Japan.

Key Market Highlights: -

• By Disease Type, the Granulomatosis with Polyangiitis dominated the market and holds approximately 50% share in 2025 and is projected to grow at a substantial CAGR during the forecast period.
• By Treatment, the RITUXIMAB dominated the market and holds approximately 65% share in 2025 and is projected to grow at a substantial CAGR during the forecast period.
• By Disease Stage, the Relapsed Manufacturers segment dominated the market and holds approximately 60% share in 2025 and is projected to grow at a substantial CAGR during the forecast period.
• In Japan, the Nanbyo designation limits monthly medical copayments based on income for AAV patients, thus removing cost barriers to biologics and creating a sustained demand for advanced remission-induction therapies across the country.

How is Technology Driving Growth in the Japan ANCA Vasculitis Treatment Market?

Technology is the basic driver of growth in the Insertable Cardiac Monitors (ICM) market in Japan and is Technology is one of the major growth drivers in the Japan ANCA Vasculitis Treatment Market. The advanced diagnostic biomarker testing accelerates the diagnosis of the MPO-ANCA-associated subtypes, which are common among Japanese patients. Advances in recombinant DNA and bioengineering have led to the development of B-cell depleting monoclonal antibodies, such as rituximab, which improve remission-induction outcomes while reducing the need for high-dose glucocorticoids. At the same time, precision medicine and small-molecule therapies that inhibit complement improve the specificity of treatments through targeting of the underlying inflammatory pathways. Digital health tools such as telemedicine and remote monitoring further support long-term treatment adherence and side-effect management, improving clinical outcomes across Japan’s specialized vasculitis care infrastructure.

Market Drivers

The Japan physiotherapy ANCA-Associated Vasculitis (AAV) Treatment Market is observing steady growth, driven by the fast aging population of the country. In Japan, the average age of patients at diagnosis in registries is around 69 years, indicating that the incidence of microscopic polyangiitis (MPA) rises sharply with age and suggesting that the care of the elderly is a key driver of the market. Growth is also supported by novel steroid-sparing therapies, including targeted biologics and oral small molecules such as Tavneos (avacopan), which addresses the critical need to reduce cumulative glucocorticoid toxicity in older patients. This is complemented by improved diagnostic specificity for MPO-ANCA, a growing specialist network in rheumatology and favorable orphan drug regulatory incentives, all of which will improve the speed of translation and clinical adoption, making Japan a unique, unmet-need market in the global AAV treatment landscape.

Restrain

However, avacopan market growth is hindered by the high risk of liver injury due to the high prevalence of the CYP3A5*3 allele in Japan, along with a super-aged patient base vulnerable to infection due to intensive immunosuppression.Intravenous high biologic costs, even with reimbursement support, put pressure on Nanbyo subsidy budgets, and established conservative cyclophosphamide-based protocols also limit biologic adoption compared to Western markets. Together, these factors moderate the pace of premium therapy uptake across Japan’s specialized AAV treatment landscape.

Analysis of Prices and Consumer Behaviour

Japan’s ANCA vasculitis treatment market is defined by the presence of high-quality treatment options (68% of the total market; primarily driven by the demand for advanced, clinically validated therapies for the effective management of the disease and improved patient outcomes). The price of a high quality standardized treatment with advanced therapeutic formulations and clinically proven treatment protocols is expected to be 35% more than other treatment options as the treatment would be supported by advanced therapeutic technology, quality certified pharmaceutical products and consistent clinical efficacy. Standardized treatment formulations and convenient administration methods account for about 45% of all treatment utilization of ANCA vasculitis in Japan. The amount of treatment is driven by the range of use in the clinical management setting and the requirement for sustained disease control over the long term. Demand from these applications is around 70% from specialty pharmaceutical and advanced clinical treatment segment. 55% of healthcare providers and patients ranked treatment efficacy, product quality and standardization of therapeutic outcomes as the most important factors in their purchasing behavior. Another 33% of healthcare providers and purchasers of treatment prefer to obtain therapies through bulk agreements or long-term contracts, as this allows them to lower the costs they incur in obtaining treatments, and also guaranties a consistent source of supply for patients and healthcare facilities in various parts of Japan.

Top Companies in the Japan ANCA Vasculitis Treatment Market

• Roche
• GlaxoSmithKline
• AstraZeneca
• Sanofi
• Bristol Myers Squibb
• Johnson & Johnson
• Pfizer
• Novartis
• AbbVie
• Takeda
• Chugai Pharmaceutical
• Astellas Pharma
• Kyowa Kirin
• Ono Pharmaceutical
• Nippon Shinyaku

Japan ANCA Vasculitis Treatment Market Segmentation

The Japan ANCA Vasculitis Treatment Market share is divided into six categories: By Disease Type, By Treatment, By Disease Stage, By Route of Administration, By End User, By Patient Type.

The Granulomatosis with Polyangiitis dominated the market, accounting for nearly 50% in 2025 and is expected to rise at a significant CAGR during the forecast period.

The Japan ANCA Vasculitis Treatment Market is segmented by disease type into granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, renal-limited vasculitis, systemic vasculitis, pulmonary vasculitis, neurological vasculitis, other anca-associated disorders. Among these, the Granulomatosis with Polyangiitis segment dominated the market, accounting for nearly 50% in 2025 and expected to increase at a significant CAGR during the forecast period. With higher PR3-ANCA prevalence, ENT/respiratory tract involvement and expanding biologic-driven remission protocols, GPA continues to lead in diagnosis and treatment.

The Rituximab dominated the market, accounting for nearly 65% in 2025, and is expected to rise at a significant CAGR during the forecast period.

The Japan ANCA Vasculitis Treatment Market is segmented by treatment into corticosteroids, rituximab, cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil, plasma exchange, supportive therapy. Among these, the Rituximab dominated the market, accounting for nearly 65% in 2025 and expected to increase at a significant CAGR during the forecast period. Rituximab is the preferred biologic for clinicians due to its proven efficacy in inducing remission, good reimbursement coverage and concerns regarding the toxicity of cyclophosphamide.

The Relapsed dominated the market, accounting for nearly 60% in 2025 and is expected to rise at a significant CAGR during the forecast period.

The Japan ANCA Vasculitis Treatment Market is segmented by disease stage into newly diagnosed, induction phase, maintenance phase, relapse, remission, severe disease, moderate disease, refractory disease. Among these, the Relapsed dominated the market, accounting for nearly 60% in 2025 and expected to increase at a significant CAGR during the forecast period. The recurrent nature of chronic disease, incomplete remission maintenance and persistence of MPO-ANCA require recurrent specialized retreatment, maintaining demand for treatment of relapsed segments.

Future Market Trends for the Japan ANCA Vasculitis Treatment Market: -

Aging Demographics: Japan’s super-aged population results in a direct increase in the incidence of AAV, especially microscopic polyangiitis, which raises the diagnosed patient base and supports long-term demand for specialized geriatric-focused vasculitis management therapies.

Glucocorticoid-sparing biologics and complement-inhibiting small molecules are now the preferred option for clinicians, who are shifting away from traditional immunosuppression in an effort to reduce steroid toxicity and improve remission induction outcomes across the specialized rheumatology networks in Japan.

Personalized precision medicine: Treatment strategies are increasingly tailored to MPO-ANCA subtype frequency in Japanese patients, with biomarker-driven therapy selection improving diagnostic accuracy and maintenance of long-term remission.

Recent Development

In May 2026, Kissei Pharmaceutical / Amgen to introduce revised safety labeling for Tavneos (avacopan) in Japan with mandatory serial liver monitoring following reports of drug-induced liver injury, while preserving access for those with severe active AAV

In June 2026, Amgen to present new real-world safety and efficacy data for Tavneos (avacopan) at EULAR 2026 Congress in London to support its steroid-sparing risk-benefit profile across markets including Japan.

Market Segmentation

This study forecasts revenue at Japan, regional and country levels from 2020 to 2033. Transpire Insights has segmented the Japan ANCA Vasculitis Treatment Market based on the below-mentioned segments:

Japan ANCA Vasculitis Treatment Market, By Disease Type

• Granulomatosis with Polyangiitis
• Microscopic Polyangiitis
• Eosinophilic Granulomatosis with Polyangiitis
• Renal-Limited Vasculitis
• Systemic Vasculitis
• Pulmonary Vasculitis
• Neurological Vasculitis
• Other ANCA-Associated Disorders

Japan ANCA Vasculitis Treatment Market, By Treatment

• Corticosteroids
• Rituximab
• Cyclophosphamide
• Azathioprine
• Methotrexate
• Mycophenolate Mofetil
• Plasma Exchange
• Supportive Therapy

Japan ANCA Vasculitis Treatment Market, By Disease Stage

• Newly Diagnosed
• Induction Phase
• Maintenance Phase
• Relapse
• Remission
• Severe Disease
• Moderate Disease
• Refractory Disease

Japan ANCA Vasculitis Treatment Market, By Route of Administration

• Intravenous
• Oral
• Subcutaneous
• Intramuscular
• Infusion
• Pulse Therapy
• Combination Therapy
• Other Routes

Japan ANCA Vasculitis Treatment Market, By End User

• Hospitals
• Rheumatology Centers
• Nephrology Centers
• Specialty Clinics
• Academic Medical Centers
• Infusion Centers
• Research Institutes
• Diagnostic Centers

Japan ANCA Vasculitis Treatment Market, By Patient Type

• Adults
• Elderly
• Renal Patients
• Pulmonary Patients
• Relapsed Patients
• Severe Patients
• Newly Diagnosed Patients
• Refractory Patients